Members of Congress and advocates worry a proposed rule from the Biden administration will make it harder for people to access a medication commonly used to treat opioid use disorder.
The Drug Enforcement Administration is proposing limiting telehealth prescriptions for buprenorphine to an initial 30-day supply until the patient can be seen in person by a physician.
The proposal follows a three-year period during the public health emergency where the DEA allowed providers to prescribe buprenorphine through telehealth without requiring an in-person visit — part of an effort to maintain access to care during the pandemic.
